Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open-label Phase II Study of Letrozole Plus Afatinib Versus Letrozole Alone in First-line Treatment of Advanced ER+, HER2- Postmenopausal Breast Cancer With Low ER Expression

NCT02115048 is registered in ClinicalTrials.gov with Translational Research in Oncology as lead sponsor.

NCT NCT02115048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02115048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open-label Phase II Study of Letrozole Plus Afatinib Versus Letrozole Alone in First-line Treatment of Advanced ER+, HER2- Postmenopausal Breast Cancer With Low ER Expression
Lead sponsor
Translational Research in Oncology
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2014
Completion date
November 30, 2018
Enrollment
44 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms